Orthofix Medical Inc. ( OFIX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Julie Dewey - Chief Investor Relations & Communications Officer Massimo Calafiore - President, CEO & Director Julie Andrews - Chief Financial Officer Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.
Orthofix (OFIX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago.
Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Julie B. Andrews - Chief Financial Officer Julie D.
Orthofix (OFIX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago.
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Caitlin Cronin - Canaccord Genuity Jeffrey Cohen - Ladenburg Operator Thank you for standing by. My name is Tina, and I will be your conference operator today.
Orthofix (OFIX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX). Investors who purchased Orthofix securities prior to October 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OFIX.
Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix Third Quarter 2024 Earnings Call. I am Fran, and I'll be the operator assisting you today.
NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class").
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to earnings of $0.07 per share a year ago.
NEW YORK CITY, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired SeaSpine shareholders who acquired newly issued Orthofix common stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction (the "Merger") by which Orthofix merged with and acquired SeaSpine (the "Class").